Lattice Capital Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Lattice Capital Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-51,800	Closed	-$26	–	29
2024 Q4	$26	Hold	51,800	–	–	﹤0.01%	29
2024 Q3	$207	Hold	51,800	–	–	﹤0.01%	28
2024 Q2	$492	Hold	51,800	–	–	﹤0.01%	31
2024 Q1	$414	Hold	51,800	–	–	﹤0.01%	21
2023 Q4	$6.4K	Buy	+51,800	New	+$6.4K	﹤0.01%	24
2023 Q2	–	Sell	-51,800	Closed	-$18.6K	–	57
2023 Q1	$18.6K	Sell	51,800 -11,400	-18%	-$10.2K	﹤0.01%	58
2022 Q4	$56K	Hold	63,200	–	–	0.01%	51
2022 Q3	$99K	Hold	63,200	–	–	0.16%	54
2022 Q2	$174K	Hold	63,200	–	–	0.32%	55
2022 Q1	$119K	Hold	63,200	–	–	0.17%	68
2021 Q4	$294K	Buy	+63,200	New	+$392K	0.02%	65

Other funds holding SRNE

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Lattice Capital Management's SRNE Position: Q1 2025 in Review

Lattice Capital Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2025, closing a stake of 51,800 shares — an estimated $26 sold.

Lattice Capital Management first reported a position in SRNE in Q4 2021 and held it in 11 quarters. The position peaked at $294K in Q4 2021. 4 funds tracked by Wall St. Rank hold SRNE as of Q1 2025.

Lattice Capital Management reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Lattice Capital Management sold 51,800 Sorrento Therapeutics, Inc. shares in Q1 2025, an estimated $26.
Lattice Capital Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2021 and held it in 11 quarters.
Lattice Capital Management's Sorrento Therapeutics, Inc. position peaked at $294K in Q4 2021.
4 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2025.

Based on Lattice Capital Management's 13F filing for Q1 2025, filed 30 Apr 2025.